<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675242</url>
  </required_header>
  <id_info>
    <org_study_id>NCX-4251-02</org_study_id>
    <nct_id>NCT04675242</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis</brief_title>
  <acronym>Mississippi</acronym>
  <official_title>Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicox Ophthalmics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicox Ophthalmics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial&#xD;
      evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal)&#xD;
      Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Complete Cure (Score 0) of Blepharitis Signs and Symptoms</measure>
    <time_frame>Day 15 Visit</time_frame>
    <description>Proportion of subjects with Complete Cure (Score 0) in each of the following: Eyelid Margin Redness (0-none, 1-mild, 2-moderate, 3-severe), Eyelid Debris (0-none, 1-mild, 2-moderate, 3-severe), and Eyelid Discomfort (0-none, 1-mild, 2-moderate, 3-severe) at the Day 15 Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eye Dryness Symptoms</measure>
    <time_frame>Day 15 Visit</time_frame>
    <description>Mean change from baseline in the eye dryness symptoms using a visual analogue scale (0 = no discomfort to 100 = maximal discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye Dryness Sign</measure>
    <time_frame>Day 15 Visit</time_frame>
    <description>Mean change from baseline in fluorescein staining of the inferior cornea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>NCX 4251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 4251 Ophthalmic Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of NCX 4251 Ophthalmic Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NCX 4251</intervention_name>
    <description>NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily</description>
    <arm_group_label>NCX 4251</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  documented history of blepharitis and meet qualifying criteria for an acute&#xD;
             exacerbation of blepharitis in both eyes at Screening and Baseline/Day 1 Visits&#xD;
&#xD;
          -  have a qualifying best-corrected visual acuity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid&#xD;
             surgery&#xD;
&#xD;
          -  IOP &gt; 21 mmHg at Screening or Baseline/Day 1 Visits&#xD;
&#xD;
          -  use of steroids in the past 30 days or retinoids in the past 12 months&#xD;
&#xD;
          -  uncontrolled systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Boyer, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nicox Ophthalmics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

